Tetraphase Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted approval of XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections (cIAI).    In clinical trials, XERAVA was well-tolerated and achieved high clinical cure rates in patients with cIAI, demonstrating statistical non-inferiority to two widely used comparators – ertapenem and meropenem. XERAVA is indicated for the treatment of complicated intra-abdominal in...